CCDC134 and neoplasm: Here we further identify that Ccdc134 deficiency accelerates TCR downmodulation by ubiquitinating CD3ε and its downstream pathways following TCR activation, rendering mice refractory to T cell-mediated inflammatory and anti-tumor responses.